NCT00601731View on ClinicalTrials.gov

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

PHASE2CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

September 30, 2010

Conditions
Meningococcal Disease
Interventions
BIOLOGICAL

MenACWY-CRM197

Blood test, 40-months and 60-months children

BIOLOGICAL

Blood test

Blood test, 40-months and 60-months children

Trial Locations (3)

Unknown

Clinical Trials Research Center, Halifax

Vaccine Evaluation Center, Vancouver

OX3 7LJ

Oxford Vaccine Group, Oxford

Sponsors

Lead Sponsor

Novartis Vaccines

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Novartis Vaccines

INDUSTRY

NCT00601731 - Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months | Biotech Hunter | Biotech Hunter